SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):293P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Simon, J.
Right arrow Articles by Frank, R. K.
PubMed
Right arrow Articles by Simon, J.
Right arrow Articles by Frank, R. K.

Radiopharmaceutical Chemistry: New Chemistry-Oncology

New Chemistry-Oncology Posters

Liquid brachytherapy, direct administration of therapeutic isotopes into tumors

Jaime Simon1, Stanley Stearns2, Kenneth McMillan1, H. Max Loy2 and R. Keith Frank1

1 IsoTherapeutics Group LLC, Angleton, Texas; 2 Valco Instruments Co. Inc., Houston, Texas

1251

Objectives: Intratumor adminstration and retention of rare earth therapeutic isotopes.

Methods: Lu-177, Sm-153, Ho-166 were administered to brain, prostate, bone, and soft tissue tumors using chromatographic micro syringes, micro drills and small pumps. Gamma images and dissection data were used to determine the amount of isotope remaining as a function of time and form of the isotope.

Results: We have found microsyringes, miniature drills and low volume pumps were easy to use and capable of delivering isotopes accurately even when penetrating bone. Stable chelates were less retained at the site of injection than weak chelates. Low pH formulations showed rapid redistribution of the isotope outside the injection site. High pH formulations were retained at the site of injection with little migration of the isotope for up to 10 days. HT-29 tumors-bearing mice injected with high pH formulations showed a reduction of tumor growth compared to controls.

Conclusions: Rare earth isotopes administered at high pH are retained with minimal loss of isotope from the site of injection. The system developed warrants further investigation for the use in treating cancers such as bone, prostate, brain, pancreatic and inoperable tumors.

Research Support: Gabriel Institute / IsoTherapeutics Group LLC


Figure 1
Injected Dose Found Two Hours after Injection Into Rat Femur





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Simon, J.
Right arrow Articles by Frank, R. K.
PubMed
Right arrow Articles by Simon, J.
Right arrow Articles by Frank, R. K.